HealthPharma & Biotech
viewReNeuron Group PLC

ReNeuron Group head of research to present encouraging early data on potential cancer treatment

Dr Randolph Corteling will detail his findings at the 2018 International Society of Cell Therapy conference in Montreal

cancer cells
Has ReNeuron found a new way to tackle cancer?

ReNeuron Group Plc's (LON:RENE) shares rose on Friday after the group revealed its head of research will present exciting early-stage data on the potential use of cell-derived exomes in the treatment of cancer.  

Exosomes are nanoparticles secreted from many different types of cells and play a key role in cell-to-cell signalling.

READ: ReNeuron wins £1.5mln to fund further development of its hRPC cell therapy candidate

Early research with ExoPr0 exomes has demonstrated their potential as both a possible therapy and as a drug delivery vehicle.

Dr Randolph Corteling and his team have discovered the ExoPr0 candidate they have identified induces a process called apoptosis in cancer, which simply means cell death. It also appears to arrest cell growth.

Used in tumour models 

Using the xenograft tumour models ExoPr0 significantly reduced the mass in a number of different cancers.

When combined with the standard of care for the various growths, the ReNeuron discovery brought about an "additive reduction of tumour volume".

It should be cautioned that this is very early stage work, though nevertheless encouraging.

Corteling will deliver his findings during a podium presentation later Friday at the 2018 International Society of Cell Therapy conference in Montreal, Canada.

"We draw considerable encouragement from these new pre-clinical results and look forward to presenting further progress with the development of ExoPr0 as a potential new and highly novel cancer therapy in the months ahead," he said ahead of the gathering.

In lunchtime trading, ReNeuron shares were 3.2% higher at 62p.

 -- Adds share price --


Quick facts: ReNeuron Group PLC

Price: 147.5 GBX

Market: LSE
Market Cap: £46.95 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...



ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18

2 min read